While less common, it’s possible. C. Diff spores can spread in healthcare settings or through contact with an infected person.
Hightower is streamlining the process for C. difficile clinical trials by investigating drugs that promise better patient outcomes.
Clostridium difficile infection (CDI) is a common bacterial infection that affects the digestive tract, causing symptoms such as diarrhea, abdominal pain, and fever. Research indicates that CDI affects millions of people worldwide, with a significant impact on healthcare systems due to its recurrence and complications.
CDI can lead to severe complications such as pseudomembranous colitis and toxic megacolon, especially in vulnerable populations like elderly individuals and those with weakened immune systems. Diagnosis is typically made through stool tests, including polymerase chain reaction (PCR) assays and enzyme immunoassays (EIAs).
Hightower Clinical is dedicated to combating CDI through advanced research and clinical trials. Our efforts focus on investigating new drugs and treatment approaches to improve patient outcomes and reduce the burden of this infection on healthcare systems.
*Participation in the Clinical Trial is completely free of cost and is your choice.
*To participate, fill out the form, and someone from our research staff will call you to determine your eligibility for the Clinical Research Study
Clostridioides difficile infection (CDI) is a highly contagious bacterial infection that affects the colon and often leads to severe diarrhea and intestinal inflammation. It stands as a formidable challenge in healthcare settings, with a notable impact on patient morbidity and mortality. In the United States, CDI contributes to approximately 223,900 cases annually.
Hightower Clinical Research is addressing this urgent medical need by leading investigations into the efficacy and safety of innovative treatment approaches for CDI. One such promising avenue involves the administration of investigational drugs via colonoscopy to adults grappling with recurrent Clostridium difficile infection.
*All study procedures and study-related treatment, including the investigational drug, are free of cost, and insurance is not required to participate.
*The study doctor will take you through every step of the Clinical Trial before you decide to participate and will answer any questions you have about the study treatment.
If you decide to participate in the Clostridium Difficile Clinical Trials in Oklahoma City, OK, by filling out the form above, someone from the study team will contact you to determine your eligibility. The team will go over the study details with you to see if you meet the eligibility criteria for C Diff Clinical Trials.
If you meet the eligibility criteria, you’ll receive an invitation for screening at the study site, located within a 50-mile radius of your current location. The study doctors will discuss the duration and potential impact of participating in clinical trials. Feel free to ask any questions you have. Once everything is thoroughly explained, participants will be asked to sign an Informed Consent Form, emphasizing our commitment to transparency and open communication between participants and investigators.
*Study-related care is offered at no charge. Expert physicians and healthcare professionals conduct thorough physical exams and assessments.*
18 Years and older (Adult, Older Adult)
Male & Female
Clostridium Difficile
Recruiting
Clostridium difficile infection (CDI) is caused by the bacterium Clostridium difficile and typically occurs after antibiotics disrupt the balance of normal gut bacteria. This disruption allows Clostridium difficile to multiply and produce toxins that lead to inflammation and damage in the colon.
Symptoms of CDI can range from mild to severe and may include
CDI can be challenging to treat, especially in recurrent or severe cases, requiring specific antibiotics or other interventions to restore the balance of gut bacteria and alleviate symptoms
Hightower is dedicated to advancing the treatment of Clostridium difficile infection (CDI), offering hope to individuals affected by this condition. Our C. difficile clinical trials aim to explore innovative treatments that can effectively manage and potentially cure CDI.
While less common, it’s possible. C. Diff spores can spread in healthcare settings or through contact with an infected person.
Recovery time varies depending on the severity of the infection. Most cases improve within a week with proper treatment.
Yes, there are potential risks. Clinical trials are carefully monitored, and researchers explain all potential risks and benefits before your participation.